90 related articles for article (PubMed ID: 21711076)
1. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP38-44. PubMed ID: 21711076
[TBL] [Abstract][Full Text] [Related]
2. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions.
Streeter SB; Schwartzberg L; Husain N; Johnsrud M
J Oncol Pract; 2011 May; 7(3 Suppl):46s-51s. PubMed ID: 21886519
[TBL] [Abstract][Full Text] [Related]
3. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
5. Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients.
Gibson TB; Jing Y; Kim E; Bagalman E; Wang S; Whitehead R; Tran QV; Doshi JA
Manag Care; 2010 Aug; 19(8):40-7. PubMed ID: 20822071
[TBL] [Abstract][Full Text] [Related]
6. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
7. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
8. Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines.
Wong WB; Donahue A; Thiesen J; Yeaw J
J Manag Care Spec Pharm; 2023 Mar; 29(3):324-334. PubMed ID: 36692908
[No Abstract] [Full Text] [Related]
9. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
[TBL] [Abstract][Full Text] [Related]
10. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
[TBL] [Abstract][Full Text] [Related]
11. Impact of pharmacy channel on adherence to oral oncolytics.
Stokes M; Reyes C; Xia Y; Alas V; Goertz HP; Boulanger L
BMC Health Serv Res; 2017 Jun; 17(1):414. PubMed ID: 28629454
[TBL] [Abstract][Full Text] [Related]
12. Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent).
Kalsekar I; Sheehan C; Peak A
Res Social Adm Pharm; 2007 Dec; 3(4):378-91. PubMed ID: 18082874
[TBL] [Abstract][Full Text] [Related]
13. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
[TBL] [Abstract][Full Text] [Related]
14. Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Borah B; Sacco P; Zarotsky V
Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067
[TBL] [Abstract][Full Text] [Related]
15. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
16. Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation.
Wang AA; Tapia C; Bhanji Y; Campbell C; Larsen D; Gross D; Ganatra S; Qodsi M; Tellez C; Jain S
J Oncol Pharm Pract; 2020 Mar; 26(2):279-285. PubMed ID: 30943846
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
Grant RW; Singer DE; Meigs JB
Clin Ther; 2005 Jun; 27(6):773-81. PubMed ID: 16117984
[TBL] [Abstract][Full Text] [Related]
18. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis.
Kalsekar ID; Madhavan SS; Amonkar MM; Douglas SM; Makela E; Elswick BL; Scott V
Clin Ther; 2006 Feb; 28(2):306-18. PubMed ID: 16678652
[TBL] [Abstract][Full Text] [Related]
19. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
20. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.
Hansen RA; Schommer JC; Cline RR; Hadsall RS; Schondelmeyer SW; Nyman JA
Res Social Adm Pharm; 2005 Jun; 1(2):139-57. PubMed ID: 17138472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
